22-MULTI-56-IB-PMC (IDE397) An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date2/8/231/8/25

Funding

  • IDEAYA Biosciences: $31,268.00